MMP-9 expression in peripheral blood mononuclear cells and the association with clinicopathological features and prognosis of nasopharyngeal carcinoma

Clinical Chemistry and Laboratory Medicine

Volumn 49, Issue 4, 2011, Pages 705-710

  He, Jian Rong ^a,b   Qin, Han ^a,b   Ren, Ze Feng ^a,b   Cui, Cui ^a   Zhang, Ying ^a   Ranatunga, Dharshana ^a,b   Zeng, Yi Xin ^a   Jia, Wei Hua ^a,b  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^b SUN YAT SEN UNIVERSITY   (China)

Author keywords

matrix metalloproteinase 9; mRNA expression; nasopharyngeal carcinoma; peripheral blood mononuclear cells; prognosis

Indexed keywords

GELATINASE B; MESSENGER RNA;

ADULT; ARTICLE; CANCER STAGING; CLINICAL FEATURE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; NASOPHARYNX CARCINOMA; OVERALL SURVIVAL; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION;

ADULT; AGED; CASE-CONTROL STUDIES; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LEUKOCYTES, MONONUCLEAR; MALE; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; NASOPHARYNGEAL NEOPLASMS; PROGNOSIS; RNA, MESSENGER; SURVIVAL RATE; YOUNG ADULT;

EID: 79954547468     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/CCLM.2011.095     Document Type: Article

References (47)

1. Guigay J. Advances in nasopharyngeal carcinoma. Curr Opin Oncol 2008;20:264-9. (Pubitemid 351507545)
2. Young LS, Rickinson AB. Epstein-Barr virus: 40 years on. Nat Rev Cancer 2004;4:757-68. (Pubitemid 39331148)
3. Yoshizaki T, Sato H, Murono S, Pagano JS, Furukawa M. Matrix metalloproteinase 9 is induced by the Epstein-Barr virus BZLF1 transactivator. Clin Exp Metastasis 1999;17:431-6. (Pubitemid 30020001)
4. Wong TS, Kwong DL, Sham JS, Wei WI, Kwong YL, Yuen AP. Clinicopathologic significance of plasma matrix metallo-proteinase-2 and-9 levels in patients with undifferentiated nasopharyngeal carcinoma. Eur J Surg Oncol 2004;30:560-4. (Pubitemid 38701881)
5. Murphy G, Nagase H. Progress in matrix metalloproteinase research. Mol Aspects Med 2008;29:290-308.
6. Ruokolainen H, Paakko P, Turpeenniemi-Hujanen T. Expression of matrix metalloproteinase-9 in head and neck squamous cell carcinoma: a potential marker for prognosis. Clin Cancer Res 2004;10:3110-6. (Pubitemid 38619691)
7. Masson V, de la Ballina LR, Munaut C, Wielockx B, Jost M, Maillard C, et al. Contribution of host MMP-2 and MMP-9 to promote tumor vascularization and invasion of malignant kera-tinocytes. Faseb J 2005;19:234-6. (Pubitemid 40189266)
8. Roy R, Yang J, Moses MA. Matrix metalloproteinases as novel biomarkers and potential therapeutic targets in human cancer. J Clin Oncol 2009;27:5287-97.
9. Hojilla CV, Wood GA, Khokha R. Inflammation and breast can-cer: metalloproteinases as common effectors of inflammation and extracellular matrix breakdown in breast cancer. Breast Cancer Res 2008;10:205.
10. Koc M, Ediger D, Budak F, Karadag M, Oral HB, Uzaslan E, et al. Matrix metalloproteinase-9 (MMP-9) elevated in serum but not in bronchial lavage fluid in patients with lung cancer. Tumori 2006;92:149-54. (Pubitemid 43835975)
11. Wilson S, Wakelam MJ, Hobbs RF, Ryan AV, Dunn JA, Red-man VD, et al. Evaluation of the accuracy of serum MMP-9 as a test for colorectal cancer in a primary care population. BMC Cancer 2006;6:258.
12. Ruokolainen H, Paakko P, Turpeenniemi-Hujanen T Serum matrix metalloproteinase-9 in head and neck squamous cell car-cinoma is a prognostic marker. Int J Cancer 2005;116:422-7. (Pubitemid 40993339)
13. Somiari SB, Somiari RI, Heckman CM, Olsen CH, Jordan RM, Russell SJ, et al. Circulating MMP2 and MMP9 in breast cancer-potential role in classification of patients into low risk, high risk, benign disease and breast cancer categories. Int J Cancer 2006;119:1403-11. (Pubitemid 44258818)
14. Wu CY, Wu MS, Chiang EP, Chen YJ, Chen CJ, Chi NH, et al. Plasma matrix metalloproteinase-9 level is better than serum matrix metalloproteinase-9 level to predict gastric cancer evolution. Clin Cancer Res 2007;13:2054-60.
15. Fujisawa T, Kato Y, Terada A, Iguchi K, Kamiya H Matrix metalloproteinase-9 in peripheral blood eosinophils. Int Arch Allergy Immunol 1999;120(Suppl 1):65-9. (Pubitemid 29457366)
16. Grigoryev DN, Mathai SC, Fisher MR, Girgis RE, Zaiman AL, Housten-Harris T, et al. Identification of candidate genes in scleroderma-related pulmonary arterial hypertension. Transl Res 2008;151:197-207.
17. Koide H, Nakamura T, Ebihara I, Tomino Y Increased mRNA expression of metalloproteinase-9 in peripheral blood mono-cytes from patients with immunoglobulin a nephropathy Am J Kidney Dis 1996;28:32-9. (Pubitemid 26231463)
18. Ebihara I, Nakamura T, Tomino Y, Shimada N, Koide H. Metal-loproteinase-9 mRNA expression in monocytes from patients with chronic renal failure. Am J Nephrol 1998;18:305-10. (Pubitemid 28274216)
19. Matache C, Stefanescu M, Dragomir C, Tanaseanu S, Onu A, Ofiteru A, et al. Matrix metalloproteinase-9 and its natural inhibitor TIMP-1 expressed or secreted by peripheral blood mononuclear cells from patients with systemic lupus erythe-matosus. J Autoimmun 2003;20:323-31. (Pubitemid 36677524)
20. Sobin LH, Wittekind CH, editors. UICC TNM classification of malignant tumors, 5th ed. Berlin: Springer-Verlag, 1997:27-30.
21. Takeshita H, Yoshizaki T, Miller WE, Sato H, Furukawa M, Pagano JS, et al. Matrix metalloproteinase 9 expression is induced by Epstein-Barr virus latent membrane protein 1 C-terminal activation regions 1 and 2. J Virol 1999;73:5548-55. (Pubitemid 29274838)
22. Stevenson D, Charalambous C, Wilson JB. Epstein-Barr virus latent membrane protein 1 (CAO) up-regulates VEGF and TGF alpha concomitant with hyperlasia, with subsequent up-regu-lation of p16 and MMP9. Cancer Res 2005;65:8826-35. (Pubitemid 41377371)
23. Takafuji S, Ishida A, Miyakuni Y, Nakagawa T Matrix metal-loproteinase-9 release from human leukocytes. J Investig Allergol Clin Immunol 2003;13:50-5. (Pubitemid 36781523)
24. Coussens LM, Tinkle CL, Hanahan D, Werb Z. MMP-9 sup-plied by bone marrow-derived cells contributes to skin carci-nogenesis. Cell 2000;103:481-90.
25. Nozawa H, Chiu C, Hanahan D. Infiltrating neutrophils mediate the initial angiogenic switch in a mouse model of multistage carcinogenesis. Proc Natl Acad Sci USA 2006;103:12493-8. (Pubitemid 44267286)
26. Ardi VC, Kupriyanova TA, Deryugina EI, Quigley JP. Human neutrophils uniquely release TIMP-free MMP-9 to provide a potent catalytic stimulator of angiogenesis. Proc Natl Acad Sci USA 2007;104:20262-7.
27. Ardi VC, Van den Steen PE, Opdenakker G, Schweighofer B, Deryugina EI, Quigley JP. Neutrophil MMP-9 proenzyme, unencumbered by TIMP-1, undergoes efficient activation in vivo and catalytically induces angiogenesis via a basic fibro-blast growth factor (FGF-2)/FGFR-2 pathway J Biol Chem 2009;284:25854-66.
28. Teramukai S, Kitano T, Kishida Y, Kawahara M, Kubota K Komuta K, et al. Pretreatment neutrophil count as an inde-pendent prognostic factor in advanced non-small-cell lung can-cer: an analysis of Japan Multinational Trial Organisation LC00-03. Eur J Cancer 2009;45:1950-8.
29. Yamanaka T, Matsumoto S, Teramukai S, Ishiwata R, Nagai Y Fukushima M. The baseline ratio of neutrophils to lymphocytes is associated with patient prognosis in advanced gastric cancer. Oncology 2007;73:215-20. (Pubitemid 351630053)
30. Black RA, Rauch CT, Kozlosky CJ, Peschon JJ, Slack JL, Wolfson MF, et al. A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells. Nature 1997;385: 729-33. (Pubitemid 27098094)
31. Mroczko B, Groblewska M, Lukaszewicz-Zajac M, Bandurski R, Kedra B, Szmitkowski M. Pre-treatment serum and plasma levels of matrix metalloproteinase 9 (MMP-9) and tissue inhibitor of matrix metalloproteinases 1 (TIMP-1) in gastric cancer patients. Clin Chem Lab Med 2009;47:1133-9.
32. Mroczko B, Lukaszewicz-Zajac M, Wereszczynska-Siemiat-kowska U, Groblewska M, Gryko M, Kedra B, et al. Clinical significance of the measurements of serum matrix metalloproteinase-9 and its inhibitor (tissue inhibitor of metalloproteinase-1) in patients with pancreatic cancer: metalloproteinase-9 as an independent prognostic factor. Pancreas 2009;38:613-8.
33. El Houda Agueznay N, Badoual C, Hans S, Gey A, Vingert B, Peyrard S, et al. Soluble interleukin-2 receptor and metallopro-teinase-9 expression in head and neck cancer: prognostic value and analysis of their relationships. Clin Exp Immunol 2007; 150:114-23. (Pubitemid 47383297)
34. Bendardaf R, Buhmeida A, Hilska M, Laato M, Syrjanen S, Syrjanen K, et al. MMP-9 (gelatinase B) expression is associ-ated with disease-free survival and disease-specific survival in colorectal cancer patients. Cancer Invest 2010;28:38-43.
35. Buhmeida A, Bendardaf R, Hilska M, Collan Y, Laato M, Syr-janen S, et al. Prognostic significance of matrix metalloprotei-nase-9 (MMP-9) in stage II colorectal carcinoma. J Gastrointest Cancer 2009;40:91-7.
36. Shah FD, Shukla SN, Shah PM, Shukla HK, Patel PS. Clinical significance of matrix metalloproteinase 2 and 9 in breast can-cer. Indian J Cancer 2009;46:194-202.
37. Buergy D, Weber T, Maurer GD, Mudduluru G, Medved F, Leupold JH, et al. Urokinase receptor, MMP-1 and MMP-9 are markers to differentiate prognosis, adenoma and carcinoma in thyroid malignancies. Int J Cancer 2009;125:894-901.
38. Saussez S, Cludts S, Capouillez A, Mortuaire G, Smetana K Jr, Kaltner H, et al. Identification of matrix metalloproteinase-9 as an independent prognostic marker in laryngeal and hypopha-ryngeal cancer with opposite correlations to adhesion/growth-regulatory galectins-1 and-7. Int J Oncol 2009;34:433-9.
39. Chen ZB, Shen SQ, Ding YM, Wang WX, Tao JP, Liang LJ, et al. The angiogenic and prognostic implications of VEGF, Ang-1, Ang-2, and MMP-9 for hepatocellular carcinoma with background of hepatitis B virus. Med Oncol 2009;26:365-71.
40. Zhong WD, Han ZD, He HC, Bi XC, Dai QS, Zhu G, et al. CD147, MMP-1, MMP-2 and MMP-9 protein expression as significant prognostic factors in human prostate cancer. Oncology 2008;75:230-6.
41. Martins SJ, Takagaki TY, Silva AG, Gallo CP, Silva FB, Cape-lozzi VL. Prognostic relevance of TTF-1 and MMP-9 expres-sion in advanced lung adenocarcinoma. Lung Cancer 2009;64: 105-9.
42. Pennanen H, Kuittinen O, Soini Y, Turpeenniemi-Hujanen T Prognostic significance of p53 and matrix metalloproteinase-9 expression in follicular lymphoma. Eur J Haematol 2008;81: 289-97.
43. Tang JG, Li X, Chen P. Expression of matrix metalloproteinase 9 in nasopharyngeal carcinoma and association with Epstein-Barr virus infection. J Zhejiang Univ Sci 2004;5:1304-12.
44. Horikawa T, Yoshizaki T, Sheen TS, Lee SY, Furukawa M. Association of latent membrane protein 1 and matrix metallo-proteinase 9 with metastasis in nasopharyngeal carcinoma. Cancer 2000;89:715-23. (Pubitemid 30658568)
45. Bushel PR, Heinloth AN, Li J, Huang L, Chou JW, Boorman GA, et al. Blood gene expression signatures predict exposure levels. Proc Natl Acad Sci USA 2007;104:18211-6. (Pubitemid 350210846)
46. Burczynski ME, Dorner AJ. Transcriptional profiling of periph-eral blood cells in clinical pharmacogenomic studies. Pharma-cogenomics 2006;7:187-202.
47. Liew CC, Ma J, Tang HC, Zheng R, Dempsey AA. The periph-eral blood transcriptome dynamically reflects system wide biol-ogy: a potential diagnostic tool. J Lab Clin Med 2006;147: 126-32. (Pubitemid 43288168)